Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection
Varicella
About this trial
This is an expanded access trial for Varicella focused on measuring Immune compromised, Varicella Zoster Virus ( VZV) Infection, Pediatric
Eligibility Criteria
Inclusion Criteria: Signed informed consent. Cangene Corporation VariZIG™ release requirement. Any of the following at-risk patients exposed to varicella within the previous 96 hours: Immunocompromised pediatric or adult patients. Neonates (less than 1 year of age) and pre-term infants. Pregnant women. Newborns whose mothers had VZV infection shortly before delivery (< 5 days) or after (< 2 days) delivery. Healthy non-immune adults Exclusion Criteria: Hypersensitivity to blood or blood products, including intravenous (IV) or intramuscular (IM) human immunoglobulin preparations. Selective immunoglobulin A (IgA) deficiency. Evidence of VZV infection. Evidence of zoster infection. Known immunity to VZV(previous varicella infection or varicella vaccination) Severely thrombocytopenic ( platelets < 50 x 10x9 / L )